This study aims to investigate the value of 68Ga-FAPI PET/CT in the efficacy evaluation of advanced unresectable hepatocellular carcinoma patients undergoing systemic antitumor therapy.
The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo a 68Ga-FAPI PET/CT before treatment and after 3-month treatment. The imaging response measurements will be compared with the histopathological results as gold standard.
Study Type
OBSERVATIONAL
Enrollment
40
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
Shanghai, Shanghai Municipality, China
RECRUITINGThe responses to systemic antitumor therapy of advanced unresectable hepatocellular carcinoma
The tumor lesions were evaluated within one week of enrollment and at 3 months of treatment, and a comparison was made before and after. Those with improved tumor lesions were considered to have responded to the treatment, while those without improved tumor lesions were considered to have no response to the treatment.
Time frame: Within 1 week of enrollment and up to 3 months
Standardized uptake value(SUV)
SUV of 68Ga-FAPI uptake on PET/CT images for tumor lesions
Time frame: Within 1 week of enrollment and after up to 3 months
Progress free survival
Progress free survival
Time frame: 3 years
Overall survival
Overall survival
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.